These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657 [TBL] [Abstract][Full Text] [Related]
3. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients. Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447 [TBL] [Abstract][Full Text] [Related]
5. Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy. Kawazoe H; Motoki Y; Takechi Y; Shishino Y; Ido K; Suemaru K; Araki H Methods Find Exp Clin Pharmacol; 2010 Sep; 32(7):499-505. PubMed ID: 21069101 [TBL] [Abstract][Full Text] [Related]
6. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800 [TBL] [Abstract][Full Text] [Related]
8. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102 [TBL] [Abstract][Full Text] [Related]
9. Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial. Iihara H; Iwai M; Morita R; Fujita Y; Ohgino K; Ishihara T; Hirose C; Suzuki Y; Masubuchi K; Kawazoe H; Kawae D; Aihara K; Endo S; Fukunaga K; Yamazaki M; Tamura T; Kitamura Y; Fukui S; Endo J; Suzuki A Lung Cancer; 2024 Jun; 192():107801. PubMed ID: 38678830 [TBL] [Abstract][Full Text] [Related]
10. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131). Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637 [TBL] [Abstract][Full Text] [Related]
12. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy. Suzuki S; Karayama M; Inui N; Kuroishi S; Fujisawa T; Enomoto N; Nakamura Y; Yokomura K; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Hayakawa H; Suda T Med Oncol; 2016 Jul; 33(7):65. PubMed ID: 27235141 [TBL] [Abstract][Full Text] [Related]
13. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis. Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690 [TBL] [Abstract][Full Text] [Related]
14. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis. Hayashi T; Shimokawa M; Mizuki F; Matsuo K; Kawada K; Nakano T; Egawa T Support Care Cancer; 2021 Sep; 29(9):5029-5035. PubMed ID: 33590260 [TBL] [Abstract][Full Text] [Related]
16. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial. Sakai C; Shimokawa M; Iihara H; Fujita Y; Ikemura S; Hirose C; Kotake M; Funaguchi N; Gomyo T; Imai H; Hakamata J; Kaito D; Minato K; Arai T; Kawazoe H; Suzuki A; Ohno Y; Okura H Oncologist; 2021 Jun; 26(6):e1066-e1072. PubMed ID: 33811782 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638 [TBL] [Abstract][Full Text] [Related]
18. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. Perez EA Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin. Hashizume J; Higuchi N; Sato K; Kodama Y; Matsunaga N; Sakamoto T; Yamaguchi K; Nakamura T; Kitahara T; Sasaki H Biol Pharm Bull; 2016; 39(4):611-4. PubMed ID: 27040634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]